Literature DB >> 21337692

Variable expression of neurofibromatosis 1 in monozygotic twins.

Margaret B Rieley1, David A Stevenson, David H Viskochil, Brad T Tinkle, Lisa J Martin, Elizabeth K Schorry.   

Abstract

Neurofibromatosis 1 (NF1) is a common autosomal dominant disorder with high penetrance but extreme variability of expression. Monozygotic (MZ) twins with NF1 who have phenotypic discordances are a useful tool in evaluating which traits are influenced by non-hereditary influences such as second hit somatic events, environmental agents, epigenetic modification, or post-zygotic mutations. We evaluated nine sets of MZ twins and one set of MZ triplets, ages 4-18 years, for NF1 features and calculated probandwise concordance (P(C)) for each feature. MZ twins were highly concordant in numbers of café-au-lait spots (P(C) = 0.89) and cutaneous neurofibromas. IQ scores were within 10 points for all twin pairs tested, and similar patterns of learning disabilities and speech disorders were observed. Twin pairs showed significant discordance for tumors, particularly plexiform neurofibromas (P(C) = 0.40) and malignant peripheral nerves sheath tumors (MPNST), as expected if post-natal second-hit events were contributing to these features. One set of twins was concordant for multiple, large paraspinal neurofibromas, suggesting that there may be more hereditary factors involved in production of paraspinal neurofibromas. Four sets were concordant for pectus deformities of the chest (P(C) = 0.80). Three sets of twins were discordant for scoliosis (P(C) = 0.40); an additional set was concordant for scoliosis but differed in presence of dystrophic features and need for surgery. Our data suggest there are additional non-hereditary factors modifying the NF1 phenotype and causing discordancies between MZ twins. Future studies may focus on differences in epigenetic changes or somatic mosaicism which have been documented for other disease genes in MZ twins.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21337692     DOI: 10.1002/ajmg.a.33851

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  20 in total

Review 1.  A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.

Authors:  Nancy Ratner; Shyra J Miller
Journal:  Nat Rev Cancer       Date:  2015-04-16       Impact factor: 60.716

Review 2.  Epigenetics and the transition from acute to chronic pain.

Authors:  Thomas Buchheit; Thomas Van de Ven; Andrew Shaw
Journal:  Pain Med       Date:  2012-09-14       Impact factor: 3.750

3.  Phenotype categorization of neurofibromatosis type I and correlation to NF1 mutation types.

Authors:  Eungu Kang; Yoon-Myung Kim; Go Hun Seo; Arum Oh; Hee Mang Yoon; Young-Shin Ra; Eun Key Kim; Heyry Kim; Sun-Hee Heo; Gu-Hwan Kim; Mark J Osborn; Jakub Tolar; Han-Wook Yoo; Beom Hee Lee
Journal:  J Hum Genet       Date:  2019-11-28       Impact factor: 3.172

4.  Neurofibromatosis Type 1 Implicates Ras Pathways in the Genetic Architecture of Neurodevelopmental Disorders.

Authors:  Jessica A Kaczorowski; Taylor F Smith; Amanda M Shrewsbury; Leah R Thomas; Valerie S Knopik; Maria T Acosta
Journal:  Behav Genet       Date:  2020-02-05       Impact factor: 2.805

5.  EGFR-Stat3 signalling in nerve glial cells modifies neurofibroma initiation.

Authors:  J Wu; W Liu; J P Williams; N Ratner
Journal:  Oncogene       Date:  2016-10-17       Impact factor: 9.867

6.  Feasibility and Preliminary Efficacy of an Internet Support Group for Parents of a Child with Neurofibromatosis Type 1: a Pilot Study.

Authors:  S Martin; M C Roderick; R Lockridge; M A Toledo-Tamula; A Baldwin; P Knight; P Wolters
Journal:  J Genet Couns       Date:  2016-11-07       Impact factor: 2.537

7.  The Impact of Neurofibromatosis Type 1 on the Health and Wellbeing of Australian Adults.

Authors:  Hilda A Crawford; Belinda Barton; Meredith J Wilson; Yemima Berman; Valerie J McKelvey-Martin; Patrick J Morrison; Kathryn N North
Journal:  J Genet Couns       Date:  2015-04-19       Impact factor: 2.537

Review 8.  Alternative splicing of the neurofibromatosis type I pre-mRNA.

Authors:  Victoria A Barron; Hua Lou
Journal:  Biosci Rep       Date:  2012-04-01       Impact factor: 3.840

Review 9.  Emerging therapeutic targets for neurofibromatosis type 1.

Authors:  James A Walker; Meena Upadhyaya
Journal:  Expert Opin Ther Targets       Date:  2018-05-07       Impact factor: 6.902

Review 10.  Familial syndromes associated with intracranial tumours: a review.

Authors:  Adrianna M Ranger; Yatri K Patel; Navjot Chaudhary; Ram V Anantha
Journal:  Childs Nerv Syst       Date:  2013-11-06       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.